Clinical Trials

March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›

October 20, 2025 Alnylam’s Commitment to Health Literacy for All As a patient-centric organization, Alnylam is fully committed to promoting the principles of health literacy as an integral part of our innovation and culture. Read More ›

May 6, 2020 Navigating the Winding Road to Drug Approvals Learn about the winding road and key members involved in getting a new drug approved. Read More ›

March 30, 2020 Alnylam's Response to COVID-19 Learn more about Alnylam's response to the COVID-19 pandemic. Read More ›

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site

FOLLOW US